+

WO1999032657A1 - Genes essentiels de staphylococcus aureus histidine proteine kinase - Google Patents

Genes essentiels de staphylococcus aureus histidine proteine kinase Download PDF

Info

Publication number
WO1999032657A1
WO1999032657A1 PCT/US1997/023912 US9723912W WO9932657A1 WO 1999032657 A1 WO1999032657 A1 WO 1999032657A1 US 9723912 W US9723912 W US 9723912W WO 9932657 A1 WO9932657 A1 WO 9932657A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
bacterial
seq
group
growth
Prior art date
Application number
PCT/US1997/023912
Other languages
English (en)
Inventor
Bret Benton
Francois Malouin
Patrick K. Martin
Molly B. Schmid
Dongxu Sun
Original Assignee
Microcide Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microcide Pharmaceuticals, Inc. filed Critical Microcide Pharmaceuticals, Inc.
Priority to AU59033/98A priority Critical patent/AU5903398A/en
Priority to PCT/US1997/023912 priority patent/WO1999032657A1/fr
Priority to US09/082,077 priority patent/US6514746B1/en
Publication of WO1999032657A1 publication Critical patent/WO1999032657A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Definitions

  • This invention relates to the field of antibacterial treatments and to targets for antibacterial agents. In particular, it relates to genes essential for survival of a bacterial strain in vi tro or in vivo.
  • the second approach involves the identification of new targets, and the subsequent screening of compounds to find antibacterial agents affecting those targets.
  • screening can involve any of a variety of methods, including screening for inhibitors of the expression of a gene, or of the product of a gene, or of a pathway requiring that product.
  • the actual target is a protein, the inhibition of which prevents the growth or pathogenesis of the bacterium.
  • protein targets can be identified by identifying genes encoding proteins essential for bacterial growth.
  • Each pathogenic bacterial species expresses a number of different genes which are essential for growth of the bacteria in vi tro or in vivo in an infection, and which are useful targets for antibacterial agents.
  • This invention concerns the identification and use of particular essential genes and bacterial strains expressing mutant forms of those genes in the identification, characterization, and evaluation of antibacterial agents.
  • this invention also provides methods of treating bacterial infections in mammals by administering an antibacterial agent active against such a gene, and the pharmaceutical compositions effective for such treatment .
  • the Staphylococcus aureus essential genes identified in this invention the essential nature of the genes was determined by the isolation of growth conditional mutants of S. aureus, in this case temperature sensitive mutants (ts mutants) .
  • Each gene was then identified by isolating recombinant bacteria derived from the growth conditional mutant strains, which would grow under non-permissive conditions but which were not revertants .
  • These recombinant bacteria contained DNA inserts derived from the normal (i.e., wild-type) S. aureus chromosome which encoded non-mutant products which replaced the function of the products of the mutated genes .
  • the fact that a clone having such a recombinant insert can complement the mutant gene product under non- permissive conditions implies that the insert contains essentially a complete gene, since it produces functional product.
  • the Staphylococcal genes described herein have been completely sequenced and analyzed. These two genes are named espA (SEQ ID NO. 2) , encoding EspA, a polypeptide of the response regulator family (SEQ ID NO. 4), and espB (SEQ ID NO. 3), encoding EspB, a polypeptide of the histidine kinase family (SEQ ID NO. 5), respectively. These can be considered to be two separate genes or together to comprise one dicistronic gene.
  • this invention provides a method of screening for an antibacterial agent by determining whether a test compound is active against one of the identified bacterial genes.
  • These genes have been identified as essential genes by the isolation of a growth conditional mutant strain, and the complementation in recombinant strains of each of the genes, by expression from artificially-inserted DNA sequences carrying genes identified by the specified sequences of SEQ ID NO. 1-3.
  • the method is performed by providing a bacterial strain having a mutant form of a gene selected from the group of genes corresponding to SEQ. ID. NO. 1-3 or a mutant gene homologous to one of those genes .
  • the mutant form of the gene confers a growth conditional phenotype, e . g.
  • a comparison bacterial strain having a normal form of the gene is also provided and the two strains of bacteria are each contacted with a test compound, preferably under semi-permissive growth conditions. The growth of the two strains in the presence of the test compound is then compared; a reduction in the growth of the bacterial strain having the mutant form compared to the growth of the bacterial strain having the normal form of the gene indicates that the test compound is active against the particular gene.
  • antibacterial agent refers to both naturally occurring antibiotics produced by microorganisms to suppress the growth of other microorganisms, and agents synthesized or modified in the laboratory which have either bactericidal or bacteriostatic activity, e . g. , ⁇ - lactam antibacterial agents, glycopeptides, macrolides, quinolones, tetracyclines, and aminoglycosides .
  • bactericidal or bacteriostatic activity e . g. , ⁇ - lactam antibacterial agents, glycopeptides, macrolides, quinolones, tetracyclines, and aminoglycosides .
  • an antibacterial agent is bacteriostatic, it means that the agent essentially stops bacterial cell growth (but does not kill the bacteria) ; if the agent is bacteriocidal, it means that the agent kills the bacterial cells (and may stop growth before killing the bacteria) .
  • the term "active against" in the context of compounds, agents, or compositions having antibacterial activity indicates that the compound exerts an effect on a particular bacterial target or targets which is deleterious to the in vi tro and/or in vivo growth of a bacterium having that target or targets.
  • a compound active against a bacterial gene exerts an action on a target which affects an expression product of that gene .
  • the direct target of the compound may be, for example, at an upstream component which reduces transcription from the gene, resulting in a lower level of expression.
  • the compound may affect the level of translation of a polypeptide expression product, or may act on a downstream component of a biochemical pathway in which the expression product of the gene has a major biological role. Consequently, such a compound can be said to be active against the bacterial gene, against the bacterial gene product, or against the related component either upstream or downstream of that gene or expression product. While the term “active against” encompasses a range of potential activities, it also implies some degree of specificity of target. Therefore, for example, a general protease is not “active against” a particular bacterial gene which produces a polypeptide product. In contrast, a compound which specifically inhibits a particular enzyme is active against that enzyme and against the bacterial gene which codes for that enzyme.
  • in vivo in the context of a bacterial infection refers to the host infection environment, as distinguished, for example, from growth of the bacteria in an artificial culture medium ( e . g. , in vi tro) .
  • bacterial gene should be understood to refer to a unit of bacterial heredity as found in the chromosome of each bacterium. Each gene is composed of a linear chain of deoxyribonucleotides which can be referred to by the sequence of nucleotides forming the chain. Thus, “sequence” is used to indicate both the ordered listing of the nucleotides which form the chain, and the chain, itself, which has that sequence of nucleotides.
  • RNA messenger RNAs
  • mRNAs messenger RNAs
  • “expressed bacterial gene” means that, in a bacterial cell of interest, the gene is transcribed to from RNA molecules .
  • the mRNA is translated to form polypeptides.
  • “expressed” means that a gene product is formed at the biological level which would normally have the relevant biological activity (i.e., RNA or polypeptide level) .
  • the term “corresponds” or “corresponding” indicates that the specified sequence identifies the gene. Therefore, a sequence which will uniquely hybridize with a gene from the relevant bacterium corresponds to that gene (and the converse) .
  • the specified sequences have the same sequence (a low level of sequencing error or individual variation does not matter) as portions of the gene or flanking sequences.
  • correspondence is shown by a transcriptional, or reverse transcriptional relationship.
  • Many genes can be transcribed to form mRNA molecules. Therefore, there is a correspondence between the entire DNA sequence of the gene and the mRNA which is, or might be, transcribed from that gene; the correspondence is also present for the reverse relationship, the messenger RNA corresponds with the DNA of the gene.
  • This correspondence is not limited to the relationship between the full sequence of the gene and the full sequence of the mRNA, rather it also exists between a portion or portions of the DNA sequence of the gene and a portion or portions of the RNA sequence of the mRNA. Specifically it should be noted that this correspondence is present between a portion or portions of an mRNA which is not normally translated into polypeptide and all or a portion of the DNA sequence of the gene.
  • hybridize has its usual meaning from molecular biology. It refers to the formation of a base- paired interaction between nucleotide polymers.
  • base pairing implies that at least an appreciable fraction of the nucleotides in each of two nucleotide sequences are complementary to the other according to the usual base pairing rules .
  • the exact fraction of the nucleotides which must be complementary in order to obtain stable hybridization will vary with a number of factors, including nucleotide sequence, salt concentration of the solution, temperature, and pH.
  • the DNA sequence of a gene or the RNA sequence of an mRNA "corresponds" to the polypeptide encoded by that gene and mRNA.
  • This correspondence between the mRNA and the polypeptide is established through the translational relationship; the nucleotide sequence of the mRNA is translated into the amino acid sequence of the polypeptide.
  • bacterial gene product or “expression product” is used to refer to a polypeptide or RNA molecule which is encoded in a DNA sequence according to the usual transcription and translation rules, which is normally expressed by a bacterium.
  • the term does not refer to the translation of a DNA sequence which is not normally translated in a bacterial cell.
  • the term does include the translation product of a portion of a complete coding sequence and the translation product of a sequence which combines a sequence which is normally translated in bacterial cells translationally linked with another DNA sequence.
  • the gene product can be derived from chromosomal or extrachromosomal DNA, or even produced in an in vi tro reaction.
  • an "expression product" is a product with a relevant biological activity resulting from the transcription, and usually also translation, of a bacterial gene.
  • a DNA containing a specific bacterial gene is obtainable using a shorter, unique probe (s) with readily available molecular biology techniques. If the method for obtaining such gene is properly performed, it is virtually certain that a longer DNA sequence comprising the desired sequence (such as the full coding sequence or the full length gene sequence) will be obtained. Thus, “obtainable by” means that an isolation process will, with high probability (preferably at least 90%, more preferably at least 95%) , produce a DNA sequence which includes the desired sequence. Thus, for example, a full coding sequence is obtainable by hybridizing the DNA of two PCR primers appropriately derived from the sequences of SEQ ID NO.
  • PCR 1-3 corresponding to a particular complementing clone to a Staphylococcus aureus chromosome, amplifying the sequence between the primers, and purifying the PCR products.
  • the PCR products can then be used for sequencing the entire gene or for other manipulations.
  • Those skilled in the art will understand the included steps, techniques, and conditions for such processes.
  • the full coding sequence or full gene is clearly not limited to a specific process by which the sequence is obtainable. Such a process is only one method of producing the final product.
  • a "mutant form" of a gene is a gene which has been altered, either naturally or artificially, changing the base sequence of the gene, which results in a change in the amino acid sequence of an encoded polypeptide .
  • the change in the base sequence may be of several different types, including changes of one or more bases for different bases, small deletions, and small insertions.
  • a normal form of a gene is a form commonly found in a natural population of a bacterial strain. Commonly a single form of a gene will predominate in natural populations. In general, such a gene is suitable as a normal form of a gene, however, other forms which provide similar functional characteristics may also be used as a normal gene. In particular, a normal form of a gene does not confer a growth conditional phenotype on the bacterial strain having that gene, while a mutant form of a gene suitable for use in these methods does provide such a growth conditional phenotype.
  • the term "growth conditional phenotype" indicates that a bacterial strain having such a phenotype exhibits a significantly greater difference in growth rates in response to a change in one or more of the culture parameters than an otherwise similar strain not having a growth conditional phenotype.
  • a growth conditional phenotype is described with respect to a single growth culture parameter, such as temperature.
  • a temperature (or heat-sensitive) mutant i.e., a bacterial strain having a heat-sensitive phenotype
  • such mutants preferably also show intermediate growth rates at intermediate, or semi- permissive, temperatures.
  • “semi-permissive conditions” are conditions in which the relevant culture parameter for a particular growth conditional phenotype is intermediate between permissive conditions and non-permissive conditions. Consequently, in semi-permissive conditions the bacteria having a growth conditional phenotype will exhibit growth rates intermediate between those shown in permissive conditions and non-permissive conditions. In general, such intermediate growth rate is due to a mutant cellular component which is partially functional under semi- permissive conditions, essentially fully functional under permissive conditions, and is non-functional or has very low function under non-permissive conditions, where the level of function of that component is related to the growth rate of the bacteria.
  • Method of screening means that the method is suitable, and is typically used, for testing for a particular property or effect in a large number of compounds. Therefore, the method requires only a small amount of time for each compound tested; typically more than one compound is tested simultaneously (as in a 96- well microtiter plate) , and preferably significant portions of the procedure can be automated. "Method of screening” also refers to determining a set of different properties or effects of one compound simultaneously.
  • the preferred compounds are small molecules; preferably the molecular weight (MW) of the componds will be equal or less than 3,000 daltons, more preferably equal or less than 1,500 daltons, and even more preferably equal or less than 600 daltons.
  • the invention also provides the polypeptides encoded by those genes.
  • the invention provides a method of screening for an antibacterial agent by determining the effects of a test compound on the amount or level of activity of a polypeptide gene product of one of the identified essential genes. The method involves contacting cells expressing such a polypeptide with a test compound, and determining whether the test compound alters the amount or level of activity of the expression product. The exact determination method will be expected to vary depending on the characteristics of the expression product. Such methods can include, for example, antibody binding methods, enzymatic activity determinations, and substrate analog binding assays .
  • this invention provides a method of screening for an antibacterial agent by contacting a polypeptide encoded by one of the identified essential genes, or a biologically active fragment of such a polypeptide, with a test compound, and determining whether the test compound binds to the polypeptide or polypeptide fragment.
  • the invention provides a method for identifying or evaluating an agent active on one of the identified essential genes.
  • this invention provides an isolated or purified DNA sequence at least 15 nucleotides in length, preferably 20, 30, 50, 100, or more nucleotides, which has a nucleotide base sequence which is the same as or complementary to a portion of a bacterial gene selected from the group of genes corresponding to SEQ ID NO. 1-3.
  • the DNA sequence is the same as or complementary to the base sequence of the entire coding region of a bacterial gene selected from the group of genes corresponding to SEQ ID NO. 1-3.
  • DNA molecule should be understood to refer to a linear polymer of deoxyribonucleotides, as well as to the linear polymer, base-paired with its complementary strand, forming double-strand DNA (dsDNA) .
  • dsDNA double-strand DNA
  • the term is used as equivalent to "DNA chain” or "a DNA” or “DNA polymer” or “DNA sequence”, so this description of the term meaning applies to those terms also.
  • the term does not necessarily imply that the specified "DNA molecule” is a discrete entity with no bonding with other entities.
  • the specified DNA molecule may have H-bonding interactions with other DNA molecules, as well as a variety of interactions with other molecules, including RNA molecules.
  • the specified DNA molecule may be covalently linked in a longer DNA chain at one, or both ends .
  • Any such DNA molecule can be identified in a variety of ways, including, by its particular nucleotide sequence, by its ability to base pair under stringent conditions with another DNA or RNA molecule having a specified sequence, or by a method of isolation which includes hybridization under stringent conditions with another DNA or RNA molecule having a specified sequence.
  • references to a "portion" of a DNA or RNA chain mean a linear chain which has a nucleotide sequence which is the same as a sequential subset of the sequence of the chain to which the portion refers. Such a subset may contain all of the sequence of the primary chain or may contain only a shorter sequence. The subset will contain at least 15 bases in a single strand.
  • sequence substantially the same; deletions, additions, or substitutions of specific nucleotides of the sequence, or a combination of these changes, which affect a small percentage of the full sequence will still leave the sequences substantially the same. Preferably this percentage of change will be less than 20%, more preferably less than 10%, and even more preferably less than 3%. “Same” is therefore distinguished from “identical”; for identical sequences there are no differences in nucleotide sequences.
  • nucleotide sequences or strands are complementary if they have sequences which would allow base pairing between the strands according to the usual pairing rules . This does not require that the strands would necessarily base pair at every nucleotide; two sequences can still be complementary with a low level of base mismatch such as that created by deletion, addition, or substitution of one or a few (up to 5 in a linear chain of 25 bases) nucleotides, or a combination of such changes .
  • a “coding sequence” or “coding region” refers to an open reading frame (ORF) which has a base sequence which is normally transcribed in a cell ( e . g. , a bacterial cell) to form RNA, which in most cases is translated to form a polypeptide.
  • ORF open reading frame
  • the coding region is that portion which encodes the polypeptide, excluding the portions which encode control and regulatory sequences, such as stop codons and promoter sequences .
  • isolated indicates that a naturally occurring material or organism (e . g. , a DNA sequence) has been removed from its normal environment.
  • an isolated DNA sequence has been removed from its usual cellular environment, and may, for example, be in a cell-free solution or placed in a different cellular environment.
  • a molecule such as a DNA sequence
  • the term does not imply that the molecule (sequence) is the only molecule of that type present .
  • an organism or molecule e.g., a nucleotide sequence
  • purified does not require absolute purity; instead, it indicates that the sequence, organism, or molecule is relatively purer than in the natural environment.
  • the claimed DNA could not be obtained directly from total human DNA or from total human RNA.
  • the claimed DNA sequences are not naturally occurring, but rather are obtained via manipulation of a partially purified naturally occurring substance (genomic DNA clones) .
  • the construction of a genomic library from chromosomal DNA involves the creation of vectors with genomic DNA inserts and pure individual clones carrying such vectors can be isolated from the library by clonal selection of the cells carrying the library.
  • this invention provides an isolated or purified DNA sequence which is the same as or complementary to a bacterial gene homologous to one of the above-identified bacterial genes where the function of the expression product of the homologous gene is the same as the function of the product of one of the above-identified genes.
  • a homologous gene will have a high level of nucleotide sequence similarity and, in addition, a protein product of homologous gene will have a significant level of amino acid sequence similarity.
  • the product of the homologous gene has the same biological function as the product of the corresponding gene identified above.
  • homologous refers to genes whose expression results in expression products which have a combination of amino acid sequence similarity (or base sequence similarity for transcript products) and functional equivalence, and are therefore homologous genes.
  • such genes also have a high level of DNA sequence similarity (i.e., greater than 80% when such sequences are identified among members of the same genus, but lower when these similarities are noted across bacterial genera), but are not identical. Relationships across bacterial genera between homologous genes are more easily identified at the polypeptide (i.e., the gene product) rather than the DNA level.
  • the combination of functional equivalence and sequence similarity means that if one gene is useful, e. g.
  • homologous gene is likewise useful as a target for an antibacterial agent, or for screening for such agents.
  • identification of one such gene serves to identify a homologous gene through the same relationships as indicated above.
  • homologous genes are found in other bacterial species, especially, but not restricted to, closely related species. Due to the DNA sequence similarity, homologous genes are often identified by hybridizing with probes from the initially identified gene under hybridizing conditions which allow stable binding under appropriately stringent conditions (e. g. , conditions which allow stable binding with approximately 85% sequence identity) . The equivalent function of the product is then verified using appropriate biological and/or biochemical assays.
  • the invention provides an isolated or purified DNA sequence which has a base sequence which is the same as the base sequence of a mutated bacterial gene selected from one of the genes identified in the first aspect where the expression of this DNA sequence or the mutated bacterial gene confers a growth conditional phenotype in the absence of expression of a gene which complements that mutation.
  • Such an isolated or purified DNA sequence can have the base sequence which varies slightly from the base sequence of the original mutated gene but contains a base sequence change or changes which are functionally equivalent to the base sequence change or changes in the mutated gene. In most cases, this will mean that the DNA sequence has the identical bases at the site of the mutation as the mutated gene.
  • the encoded expression products are also provided.
  • another aspect concerns a purified, enriched, or isolated polypeptide, which is encoded by one of the identified essential genes.
  • a polypeptide may include the entire gene product or only a portion or fragment of the encoded product.
  • Such fragments are preferably biologically active fragments which retain one or more of the relevant biological activities of the full size gene product .
  • bacterial strains expressing a mutated form of one of the above identified genes, which confers a growth conditional phenotype are useful for evaluating and characterizing the gene as an antibacterial target and for screening for antibacterial agents. Therefore, this invention also provides a purified bacterial strain expressing a mutated gene which is a mutated form of one of the bacterial genes identified above, where the mutated gene confers a growth conditional phenotype.
  • this invention provides a recombinant bacterial cell containing an artificially inserted DNA construct which contains a DNA sequence which is the same as or complementary to one of the above-identified bacterial genes or a portion of one of those genes.
  • Such cells are useful, for example, as sources of probe sequences or for providing a complementation standard for use in screening methods .
  • recombinant bacterial cell has its usual molecular biological meaning.
  • the term refers to a microbe into which has been inserted, through the actions of a person, a DNA sequence or construct which was not previously found in that cell, or which has been inserted at a different location within the cell, or at a different location in the chromosome of that cell.
  • Such a term does not include natural genetic exchange, such as conjugation between naturally occurring organisms.
  • a recombinant bacterium could have a DNA sequence inserted which was obtained from a different bacterial species, or may contain an inserted DNA sequence which is an altered form of a sequence normally found in that bacteria.
  • this invention provides a method of diagnosing the presence of a bacterial strain having one of the genes identified above, by probing with an oligonucleotide at least 15 nucleotides in length, which specifically hybridizes to a nucleotide sequence which is the same as or complementary to the sequence of one of the bacterial genes identified above.
  • an oligonucleotide at least 15 nucleotides in length, which specifically hybridizes to a nucleotide sequence which is the same as or complementary to the sequence of one of the bacterial genes identified above.
  • it is practical to detect the presence of a particular bacterial strain by direct hybridization of a labeled oligonucleotide to the particular gene.
  • a longer oligonucleotide is used, for example, at least 20, 30, 50, or 100 nucleotides in length.
  • this invention provides a method of diagnosing the presence of a bacterial strain by specifically detecting the presence of the transcriptional or translational product of the gene.
  • a transcriptional (RNA) product is detected by hybridizing a labeled RNA or DNA probe to the transcript.
  • Detection of a specific translational (protein) product can be performed by a variety of different tests depending on the specific protein product. Examples would be binding of the product by specific labeled antibodies and, in some cases, detection of a specific reaction involving the protein product .
  • oligonucleotide probes As described above, the presence of a specific bacterial strain can be identified using oligonucleotide probes. Therefore this invention also provides such oligonucleotide probes at least 15 nucleotides in length, which specifically hybridize to a nucleotide sequence which is the same as or complementary to a portion of one of the bacterial chains identified above.
  • this invention provides a method of treating a bacterial infection in a mammal by administering a compound which is active against a bacterial gene selected from the group of genes corresponding to SEQ ID NO. 1-3, comprising espA and espB.
  • the infection involves a bacterial strain expressing a gene corresponding to one of the specified sequences, or a homologous gene.
  • homologous genes provide equivalent biological function in other bacterial species.
  • Treating in this context, refers to administering a pharmaceutical composition for prophylactic and/or therapeutic purposes.
  • prophylactic treatment refers to treating a patient who is not yet infected, but who is susceptible to, or otherwise at risk, of a particular infection.
  • therapeutic treatment refers to administering treatment to a patient already suffering from an infection.
  • bacterial infection refers to the invasion of the host mammal by pathogenic bacteria. This includes the excessive growth of bacteria which are normally present in or on the body of a mammal. More generally, a bacterial infection can be any situation in which the presence of a bacterial population (s) is damaging to a host mammal.
  • a mammal is "suffering" from a bacterial infection when excessive numbers of a bacterial population are present in or on a mammal's body, or when the effects of the presence of a bacterial population (s) is damaging the cells or other tissue of a mammal .
  • administration refers to a method of giving a dosage of an antibacterial pharmaceutical composition to a mammal, where the method is, e . g. , topical, oral, intravenous, transdermal, intraperitoneal, or intramuscular.
  • the preferred method of administration can vary depending on various factors, e . g. , the components of the pharmaceutical composition, the site of the potential or actual bacterial infection, the bacterium involved, and the severity of an actual bacterial infection.
  • mammamal refers to any organism of the Class Mammalia of higher vertebrates that nourish their young with milk secreted by mammary glands, e . g. , mouse, rat, and, in particular, human, dog, and cat.
  • the invention provides a method for treating a bacterial infection in a mammal by administering an amount of an antibacterial agent effective to reduce the infection.
  • the antibacterial agent specifically inhibits a biochemical pathway requiring the expression product of a gene corresponding to one of the genes identified in the first aspect above. Inhibition of that pathway inhibits the growth of the bacteria in vivo.
  • the antibacterial agent inhibits the expression product of one of the identified genes.
  • biochemical pathway refers to a connected series of biochemical reactions normally occurring in a cell, or more broadly a cellular event such as cellular division or DNA replication.
  • steps in such a biochemical pathway act in a coordinated fashion to produce a specific product or products or to produce some other particular biochemical action.
  • Such a biochemical pathway requires the expression product of a gene if the absence of that expression product either directly or indirectly prevents the completion of one or more steps in that pathway, thereby preventing or significantly reducing the production of one or more normal products or effects of that pathway.
  • an agent specifically inhibits such a biochemical pathway requiring the expression product of a particular gene if the presence of the agent stops or substantially reduces the completion of the series of steps in that pathway.
  • Such an agent may, but does not necessarily, act directly on the expression product of that particular gene .
  • the invention provides a method of inhibiting the growth of a pathogenic bacterium by contacting the bacterium with an antibacterial agent which specifically inhibits a biochemical pathway requiring the expression product of a gene selected from the group of genes corresponding to SEQ ID NO. 1-3 or a homologous gene. Inhibition of that pathway inhibits growth of the bacterium.
  • the antibacterial agent inhibits the expression product of one of the identified genes.
  • inhibiting the growth indicates that the rate of increase in the numbers of a population of a particular bacterium is reduced.
  • the term includes situations in which the bacterial population increases but at a reduced rate, as well as situations where the growth of the population is stopped, as well as situations where the numbers of the bacteria in the population are reduced or the population even eliminated.
  • a "pathogenic bacterium” includes any bacterium capable of infecting and damaging a mammalian host, and, in particular, includes Staphylococcus aureus .
  • the term includes both virulent pathogens which, for example, can cause disease in a previously healthy host, and opportunistic pathogens which can only cause disease in a weakened or otherwise compromised host.
  • the invention provides a method of prophylactic treatment of a mammal by administering a compound active against a gene selected from the group of genes corresponding to SEQ ID NO. 1-3 to a mammal at risk of a bacterial infection.
  • a mammal may be at risk of a bacterial infection, for example, if the mammal is more susceptible to infection or if the mammal is in an environment in which infection by one or more bacteria is more likely than in a normal setting. Therefore, such treatment can, for example, be appropriate for an immuno-compromised patient.
  • a method of making an antibacterial agent involves screening for an agent active on one of the identified essential genes by providing a bacterial strain having a mutant form of one of the genes corresponding to SEQ ID NO. 1-3, or a homologous gene. As described above, the mutant form of the gene confers a growth conditional phenotype .
  • a comparison bacterial strain is provided which has a normal form of said gene. The bacterial strains are contacted with a test compound in semi-permissive growth conditions, and the growth of the strains are compared to identify an antibacterial agent. The identified agent is synthesized in an amount sufficient to provide the agent in a therapeutically effective amount to a patient.
  • this invention provides a pharmaceutical composition appropriate for use in the methods of treating bacterial infections described above, containing a compound active on a bacterial gene selected from the group of genes described above and a pharmaceutically acceptable carrier. Also, in a related aspect the invention provides a novel compound having antibacterial activity against one of the bacterial genes described above.
  • a “carrier” or “excipient” is a compound or material used to facilitate administration of the compound, for example, to increase the solubility of the compound.
  • Solid carriers include, e . g. , starch, lactose, dicalcium phosphate, sucrose, and kaolin.
  • Liquid carriers include, e . g. , sterile water, saline, buffers, non-ionic surfactants, and edible oils such as peanut and sesame oils.
  • various adjuvants such as are commonly used in the art may be included.
  • antibacterial activity indicates that the presence of a particular compound in the growth environment of a bacterial population reduces the growth rate of that population, without being a broad cellular toxin for other categories of cells.
  • Fig. 2 shows the nucleotide se-quence of the espAB operon along with the encoded amino acid sequences of EspA and EspB.
  • Fig. 3 shows alignment of EspA sequence from S. aureus (Sau) with the translated nucleotide sequences of genes having sequence similarity but of unknown function from Bacillus subtilis (Bsu) and Streptococcus pyogenes
  • Fig. 4 shows a scheme for disrupting the espB gene .
  • Fig. 5 schematically illustrates the expected cellular localization of the espA and espB gene products.
  • Fig. 6 shows the percent inhibition of growth by a natural product extracts screening hit (HEPA screen) at a range of concentrations against 3 S. aureus strains, wild-type strain 8325-4, NT372 ts mutant, and the complemented ts mutant, SAM533.
  • this invention concerns essential genes in Staphylococcus aureus, in particular the operon containing the espA and espB coding sequences and the espA and espB genes separately.
  • This organism is a serious pathogen which frequently carries resistance to a variety of existing antibiotic agents.
  • Such resistant strains of S. aureus are a particular problem in settings where antibacterial agents are intensively used, such as in hospitals.
  • new classes of antibiotic drugs be found, particularly ones which are active against new bacterial targets. While such bacterial targets are usually (though not always) proteins, the targets can be identified by first identifying the bacterial genes which encode proteins (or RNA transcripts) that are essential for growth of the bacteria.
  • conditional lethal mutant strains Such mutant strains will grow under permissive conditions, but will not grow, or grow very poorly under non-permissive conditions.
  • temperature sensitive mutants provided the growth conditional phenotype.
  • the particular gene in each strain which was mutated to confer a growth conditional phenotype was then identified by isolating recombinant derivatives of the mutant strains .
  • These recombinant strains each contained a DNA insert which, when expressed, would complement the defective gene and thus would allow growth under non-permissive conditions.
  • DNA inserts were provided by a genomic library of a normal S. aureus chromosome.
  • the ability of the DNA insert in the recombinant strain to complement the defective product of the mutated gene showed that the DNA insert contained essentially a complete gene corresponding to a particular mutated gene .
  • the vectors carrying each of these DNA inserts were constructed such that the S. aureus chromosomal insert could be amplified by PCR using flanking primer sequences. Each of the amplified S. aureus inserts was then sequenced, in general from both the 5 ' and 3 ' ends .
  • the sequences described herein are believed to be correct, however, it is possible that the specified sequences may contain a low level of sequence errors compared to the actual gene sequence. However, any possible errors can be readily corrected by one skilled in the art by resequencing the gene using standard methods.
  • the complete gene and gene sequence can be reliably obtained by any of several different methods. For example, probes can be constructed based on the partial sequences provided, which can be used to probe genomic or cDNA libraries of S. aureus . Clones containing the corresponding 5 ' and 3 ' sequences can then be further characterized and sequenced to provide the complete gene .
  • the partial 5' and 3' sequences can be used to construct PCR primer sequences which can be used to amplify the sequence between those primers and likewise provide the complete gene.
  • equivalent growth conditional mutant strains can be obtained by following the same or a similar process of mutagenizing the base S. aureus strain, and then likewise obtaining the complete gene by isolating complementing clones which correspond to the sequences provided, from a genomic or cDNA library. It should again be noted that, for any of these approaches, a low level of sequencing error in the sequence presented herein does not matter, since the stringency of the hybridizing conditions can be readily adjusted to provide the appropriately specific binding.
  • genes identified in this invention are highly useful as targets for novel antibacterial therapy, the genes and parts of those genes are also useful to provide probes which can be used to identify the presence of a particular bacteria carrying a particular gene.
  • the growth conditional mutant strains described above are also useful as tools in methods for screening for antibacterial agents which target that gene (targeting the corresponding normal gene) . The methods involved in the identification of the mutant strains complementing recombinant clones and the particular genes are described in more detail below.
  • the growth conditional mutant strains and recombinant strains herein are based on S. aureus strain 8325-4. This strain has been the subject of substantial genetic characterization and is appropriate for use in the approach described herein. It is believed to be free of transposons, phage or extrachromosomal elements. Numerous other strains of S. aureus can likewise be used. However, it is advantageous to select a strain which has few, or preferably no, transposons or extrachromosomal elements, as such elements can complicate the genetic analysis.
  • Heat-sensitive mutants were obtained after diethyl sulfate (DES; SIGMA Chemical) mutagenesis of strain 8325-4. Briefly, single colonies were inoculated into LB broth in individual wells of a 96-well microtiter plate and grown overnight (35°C, 18 h) . Culture supematants (10 ⁇ l) were diluted into ⁇ -dilution buffer
  • the S. aureus strain used for the preparation of genomic DNA for library construction as well as for the generation of conditional-lethal (temperature sensitive) mutants described in this document is a derivative of NCTC 8325, designated as 8325-4 (Novick, R.P., 1990).
  • the 8325 parent strain is one of the better-characterized strains of S. aureus, with genetic and physical map data available in the current literature (Pattee, P.A., 1990).
  • the 8325-4 derivative strain has all the chromosomal elements of the parent, with the exception of integrated ( i . e . , prophage and transposon DNA) and extrachromosomal (i.e., plasmid DNA) elements endogenous to the parent .
  • Cloning and subcloning experiments utilized the commercially-available E. coli strains JM109 (Promega) and DH5alpha (GIBCO-BRL) . All enzymes cited (i.e., restriction endonucleases, ligases and phosphatases) were obtained commercially (NEB, Promega) . All DNA cloning and manipulations are described in the current literature (Sambrook, et al . , 1989). Parent plasmids pE194 and pUC19 have been described previously (Horinouchi, S. et al . , 1982; Yanisch-Perron, C. et al . , 1985) Recombinant constructs for use in a S.
  • aureus host were first electroporated (Gene Pulser, BioRad) into S. aureus strain RN4220 (a restriction-deficient but ethylase-proficient strain; Novick, R.P., 1990) before transduction into the target strain for complementation and cross-complementation analyses.
  • D. Library Construction The shuttle plasmid vector used was pMP16, constructed by cloning the entire length of the natural S. aureus plasmid pE194 (linearized with Cla I) into the Nar I site of pUC19 (Yanisch-Perron et al . , 1985). This new construct replicates and offers antibiotic resistance selections in both E. coli and S. aureus .
  • Library B In constructing library B, the ends of the Sau3A I fragments were partially filled with dGTP and dATP, ligated with linearized (Sal I) pMP16 that was partially filled with dCTP and dTTP, and transformed into E. coli .
  • the advantage of partially filling the ends is that DNAs with the same ends can no longer ligate to each other; the majority of the ligation occurs between the vector and inserts, significantly increasing the percentage of insert-containing clones.
  • the chance that two unrelated insert fragment are fortuitously ligated in the same clone is greatly reduced by using this strategy.
  • Library B consists of 50,000 independent clones with > 98% containing inserts. Both library A and library B contain at least a 50-fold representation of the S. aureus genome.
  • Clones from the two libraries were pooled and plasmid DNA extracted.
  • the DNAs were used to transform S. aureus strain RN4220.
  • About 100,000 erythromycin resistant transformants were pooled and infected with bacteriophage ⁇ ll at a multiplicity of infection (MOD of 0.01 to generate phage lysates containing the shuttle library plasmids.
  • the lysates were then used to introduce the shuttle plasmids into ts mutants by transduction to isolate complementing clones.
  • 8325-4 was generated following a procedure essentially as described in Camilli et al . , 1990, J. Bacteriol . 172:3738- 3744; briefly, 8325-4 (pLTVl) was grown at 30°C overnight (18 h.) in TSB (2 mL) containing erythromycin (2 ⁇ g/mL) to post-exponential phase.
  • This Tn917 library lysate was used to transduce the NT372 mutant to a temperature-resistant phenotype; this mutant was innoculated into TSB (3 mL) and grown overnight (18 h.) at 30°C; the lysate from the Tn917 insertion library was added to give an MOI of 0.1, along with a solution of CaCl 2 (100 ⁇ L; 50 mM) and enough TSB to give a final volume of 4 mL. The mixture was incubated
  • the cell suspension was plated on TSA containing erythromycin (2 ⁇ g/mL) , sodium citrate (500 ⁇ g/mL) and Oxyrase (1:50 v/v) .
  • the plates were incubated at 30°C until colonies began to appear (48 h.); these colonies were reselected on TSA-erythromycin plates at 43 °C.
  • Transducing lysates were prepared from the newly temperature-resistant colonies and used to transduce the parent mutant to erythromycin resistance.
  • Successful transductants were replica plated at 30°C and 43°C to establish genetic linkage.
  • Transducing lysates were made from those colonies scored as temperature- sensitive and erythromycin-resistant ; these lysates were used to transduce 8325-4 to temperature sensitivity.
  • the lysate from library B was first chosen for transduction of the ts mutants because of its higher insert frequency.
  • the ts mutants were grown either in TS broth or on TS agar plates overnight (18 h) .
  • the cells were resuspended in TS broth containing CaCl 2 (5 mM) to an OD 600 between 2 - 3.
  • the lysate from library B (10-50 ⁇ l) was added to the resuspended cells (2 ml) and incubated at 30°C with slow shaking (20 m) . Ice-cold sodium citrate (20 mM; 1 ml) was added and the culture was centrifuged to pellet the cells.
  • the pellet was resuspended in ice-cold sodium citrate (20 mM; 500 ⁇ l) .
  • a small aliquot (about 1/5000 of the total volume) was plated on a TSA-ery-citrate plate (TS agar containing 5 ⁇ g/ml erythromycin and 500 ⁇ g/ml sodium citrate) and incubated at 30°C overnight (18 h) .
  • the total number of erythromycin-resistant transductants screened were estimated from this plate; at least 200,000 transductants were screened for each ts mutant to assure that the library population was well represented.
  • DNA sequence ladders were generated by thermocycle sequencing procedures based upon the use of fluorescent-labeled primers (one of T7, SP6, M13 forward and M13 reverse; ABI) , a thermostable DNA polymerase (AmpliTaq; Perkin Elmer/ABI) and dideoxy terminator chemistry (Sanger, et al, 1977, Proc. Natl . Acad. Sci . USA 74:54463) . Data were acquired on an ABI 373A automated DNA sequencer (ABI) and processed using the PRISM sequence analysis software (ABI) .
  • ABI ABI 373A automated DNA sequencer
  • ABSI PRISM sequence analysis software
  • nucleotide sequences disclosed herein For the nucleotide sequences disclosed herein, three independently generated genomic amplicons from the NT372 mutant were sequenced in parallel and were compared to a sequence derived from the parent strain (8325-4) to differentiate genomic mutations from possible PCR-induced amplification errors.
  • the nucleotide sequences disclosed herein represent the range of highest quality data acquired in multiple passes from both strands.
  • the complete nucleotide sequence of the complementing clone, including the ORFs defining the EspA and EspB polypeptides, is presented in Figure 2, along with the translated amino acids below each condon triplet.
  • the genomic point mutation producing the ts lethal phenotype of mutant NT372 occurs at position 835 of SEQ. ID. NO. 1, changing a "G" to an "A”, resulting in the predicted amino acid change at residue 63 from glutamic acid ("E") to lysine ("K”). This mutation occurs in a region highly conserved among known members
  • sequences corresponding to each complementing clone identify and provide the coding sequence (gene) responsible for providing that complementation. Therefore, the sequences corresponding to each complementing clone correspond to a particular essential gene.
  • Sequence data were analyzed for similarity to existing publicly-available database entries both at the nucleic acid level and the (putative) polypeptide level; the current releases and daily cumulative updates of these databases are maintained at the NCBI and are freely accessible.
  • the programs BLASTN Altschul, et al . , 1990, J. Mol . Biol . 215:403-410) and FASTA (Pearson, et al . , 1988, Proc. natl . Acad. Sci . USA 85:2444-2448) were used to search the nucleic acid databases GenBank (Release 102.0) and EMBL (Rel. 51.0).
  • mutant NT372 was selected for further analysis as described below.
  • Phenotype of S. aureus mutant NT372 Mutant NT372 was initially identified by its inability to survive a temperature shift to 43 °C on TSA plates for 2 hours. The ts phenotype is partially rescued at 43 °C by plating either on TSA plates supplemented with IM NaCl or Oxyrase; subsequent reselection of the surviving colonies on TSA alone at 43 °C reconfirms the ts phenotype. The phenotype does not seem to be linked to carbon source.
  • Fig. 1 schematically shows the relative position and orientation of the espA and espB ORFs.
  • the first open reading frame is preceeded by a Shine-Dalgarno sequence (AGAGG) and is believed to begin at the ATG codon at position 649, although it is also possible that the start codon could be located at the preceeding ATG at position 643.
  • the first reading frame terminates with a TAG at position 1350, resulting in a putative polypeptide of 233 amino acids with a predicted molecular mass of 27,200 Da and an isoelectric point of 5.0.
  • the second open reading frame begins with an ATG at position 1363, preceeded by a Shine-Dalgarno sequence (AGAGG) , and ends with a TAA at position 3189, resulting in a putative polypeptide of 609 amino acids with a predicted molecular mass of 69,900 Da and an isoelectric point of 5.4.
  • AGAGG Shine-Dalgarno sequence
  • AGAGG Shine-Dalgarno sequence
  • the espA ORF encodes a polypeptide of the Response Regulator family:
  • espAB encodes a two-component systems, of a type which is often involved in the regulation of cellular functions in bacteria.
  • Two-component systems use phosphorylation as a means of information transfer across the bacterial membrane.
  • environmental signals result in the autophosphorylation of a unique histidine residue in the sensor component of the system, designated the histidine protein kinase (HPK) ; the signal is further transmitted by a second phosphorylation reaction which transfers the phosphate from the HPK to a specific aspartic acid residue of the response element, designated the response regulator (RR) .
  • the activated response regulator in turn triggers the expression of an array of genes that cause the organism to express a phenotype compatible with the conditions of the growth environment.
  • the expected cellular location of the two components is shown schematically in Fig. 5.
  • chromosomal integration constructs Two chromosomal integration constructs were created to achieve disruption of eibher the response regulator or the histidine protein kinase ORF; it is important to avoid the use of ts origins of replication in the integration constructs so that the gene in question can be demonstrated to be essential at all temperatures.
  • the er-77C gene from plasmid pE194 was inserted either at the EcoR V site to disrupt the EspA open reading frame (creating pMP626) at amino acid 53, or at the Hpa I site to disrupt the EspB open reading frame (creating pMP705) at amino acid 344. (The scheme is shown in Fig.
  • espA and espB genes With the cloning and identification of espA and espB genes, it is routine for one skilled in the art to express recombinant espA and espB genes . These genes can be put under the control of a constitutive or inducible promoter in a suitable expression vector. These two genes can be either under the control of a single promoter, as in wild type S. aureus cells, or under the control of separate promoters. The vector can then be either transduced or electroporated into S. aureus cells, or other bacterial or non-bacterial cells. The vector should be selected to be compatible with the particular target cells. These two genes can be expressed simultaneously or separately in cells.
  • espA and espB genes in S. aureus cells or other organism can be used to produce a large quantity of corresponding polypeptides, which thereby make it convenient to obtain isolated, purified, or enriched polypeptides.
  • the polypeptides can then be used to study the biochemical and structural properties of espA and espB gene products . The understanding of these properties may facilitate the design of new drug to S. aureus .
  • the polypeptides can also be used to raise the antibodies against espA and espB gene products.
  • portions of either espA or espB coding sequences can also be expressed as recombinant genes.
  • the portion encodes a corresponding polypeptide fragment with a length of at least 20 amino acid.
  • the polypeptide fragments can be utilized in a similar way to corresponding full-length polypeptides.
  • homologous genes are identifiable, for example, based on a combination of hybridization of all or a portion of one gene to the complement strand of its homologous counterpart, and the ability of the homologous gene to complement the growth conditional mutant of S. aureus under non-permissive conditions.
  • the ability of the homologous gene to hybridize with sequences from the S. aureus gene provides that such a homologous gene can be readily obtained using generally accepted and used cloning techniques.
  • the ability of the homologous gene to complement a defective S. aureus gene demonstrates that the genes are essentially equivalent genes found in different bacteria.
  • Van Dijl et al describes the isolation of homologous genes by isolating clones of a host bacterial strain which contain random DNA fragments from a donor microorganism. In those clones a specific host gene has been inactivated (such as by linkage with a regulatable promoter) , and inserted homologous genes are identified by the complementation of the inactivated gene function. Homologous genes identified in this way can then be sequenced.
  • homologous gene products can often be isolated (by assaying for the appropriate activity) and at least partially sequenced (e. g. , N-terminal sequencing).
  • the amino acid sequence so obtained can then be used to deduce the degenerate DNA base sequence, which can be used to synthesize a probe (s) for the homologous gene.
  • a DNA library from another microorganism is then probed to identify a clone (s) containing a homologous gene, and the clone insert sequenced.
  • target genes are prioritized according to which are more likely to allow identification of antibacterial agents which are: 1. Highly inhibitory to the target in relevant pathogenic species;
  • target genes are prioritized using a variety of methods, such as those described below.
  • Essential genes can be characterized as either bactericidal or bacteriostatic. Earlier work with Salmonel l a mutants established that the bactericidal/bacteriostatic distinction was a characteristic of inhibition of the specific gene, rather than of a mutant allele, and could be characterized in vi tro. (Schmid et al., 1989, Genetics 123:625-633.)
  • preferred targets are those which are highly bactericidal when inhibited, causing cell death.
  • a subset of the bactericidal essential genes can be identified as strongly bactericidal, resulting in rapid cell death when inhibited.
  • null mutants in which the mutant gene product is inactive at 37°C.
  • those mutant strains can be used in this evaluation if the gene product is essentially inactive at 37°C. If such a temperature sensitive mutant has not previously been isolated but a complementing clone of some growth conditional mutant is available, then the required null mutants can generally be isolated through the use of localized mutagenesis techniques (Hong and Ames, 1971, Proc. Natl .
  • the evaluation then involves the comparison of the in vivo effects of the normal strain and the mutant strain.
  • the comparison involves determinations of the relative growth in vivo, relative bactericidal phenotype in vivo and differences in response in various infection models.
  • gene target evaluation methods such as those described above, the identified target genes are evaluated in an infection model system.
  • References herein to the use of animals or mammals should be understood to refer to particular infection models.
  • Other infection systems may be used, such as cell-based systems as surrogates for whole organism models, or systems to evaluate possible antimicrobial targets of pathogens of organisms other than animals ( e . g. , plants).
  • the criteria for evaluation include the ability of the microbe to replicate, the ability to produce specific exoproducts involved in virulence of the organism, and the ability to cause symptoms of disease in the animals.
  • the infection models e . g. , animal infection models
  • the infection models are selected primarily on the basis of the ability of the model to mimic the natural pathogenic state of the pathogen in an organism to be treated and to distinguish the effects produced by activity or by loss of activity of a gene product ( e . g. , a switch in the expression state of the gene) .
  • the models are selected for efficiency, reproducibility, and cost containment.
  • rodents especially mice, rats, and rabbits, are generally the preferred species. Experimentalists have the greatest experience with these species. Manipulations are more convenient and the amount of materials which are required are relatively small due to the size of the rodents.
  • Each pathogenic microbe (e . g. , bacterium) used in these methods will likely need to be examined using a variety of infection models in order to adequately understand the importance of the function of a particular target gene .
  • mice The mouse soft tissue infection model is a sensitive and effective method for measurement of bacterial proliferation.
  • anesthetized mice are infected with the bacteria in the muscle of the hind thigh.
  • the mice can be either chemically immune compromised (e. g. , cytoxan treated at 125 mg/kg on days - 4, -2, and 0) or immunocompetent .
  • the dose of microbe necessary to cause an infection is variable and depends on the individual microbe, but commonly is on the order of 10 5 - 10 6 colony forming units per injection for bacteria.
  • a second model useful for assessing the virulence of microbes is the diffusion chamber model (Malouin et al . , 1990, Infect . Immun . 58: 1247-1253; Doy et al., 1980, J. Infect . Dis . 2: 39-51; Kelly et al . , 1989, Infect . Immun . 57: 344-350.
  • rodents have a diffusion chamber surgically placed in the peritoneal cavity.
  • the chamber consists of a polypropylene cylinder with semipermeable membranes covering the chamber ends. Diffusion of peritoneal fluid into and out of the chamber provides nutrients for the microbes.
  • the progression of the "infection" can be followed by examining growth, the exoproduct production or RNA messages. The time experiments are done by sampling multiple chambers.
  • a fourth model useful in the evaluation of pathogenesis is the osteomyelitis model (Spagnolo et al., 1993, Infect . Immun . 61: 5225-5230) .
  • Rabbits are used for these experiments. Anesthetized animals have a small segment of the tibia removed and microorganisms are microinjected into the wound. The excised bone segment is replaced and the progression of the disease is monitored. Clinical signs, particularly inflammation and swelling are monitored. Termination of the experiment allows histolic and pathologic examination of the infection site to complement the assessment procedure.
  • Murine Septic Arthritis Model A fifth model relevant to the study of microbial pathogenesis is a murine septic arthritis model (Abdelnour et al., 1993, Infect . Immun . 61: 3879-3885). In this model mice are infected intravenously and pathogenic organisms are found to cause inflammation in distal limb joints. Monitoring of the inflammation and comparison of inflammation vs. inocula allows assessment of the virulence of related strains .
  • bacterial peritonitis offers rapid and predictive data on the virulence of strains (M.G. Bergeron, 1978, Scand. J. Infect . Dis . Suppl. 14: 189-206; S.D. Davis, 1975, Antimicrob. Agents Chemother. 8: 50-53).
  • Peritonitis in rodents preferably mice, can provide essential data on the importance of targets. The end point may be lethality or clinical signs can be monitored. Variation in infection dose in comparison to outcome allows evaluation of the virulence of individual strains .
  • target organ recovery assays may be useful for fungi and for bacterial pathogens which are not acutely virulent to animals.
  • Zak and Sande EXPERIMENTAL MODELS IN ANTIMICROBIAL CHEMOTHERAPY, 0. Zak and M.A. Sande (eds.), Academic Press, London (1986) is considered a standard.
  • immuno-incompetent animals may, in some instances, be preferable to immuno-competent animals.
  • the action of a competent immune system may, to some degree, mask the effects of altering the level of activity of the test gene product as compared to a similar infection in an immuno-incompetent animal.
  • many opportunistic infections in fact, occur in immuno- compromised patients, so modeling an infection in a similar immunological environment is appropriate.
  • the growth conditional mutants are useful for screening for inhibitors of the identified targets, even before the novel genes or biochemical targets are fully characterized.
  • the methodology can be whole-cell based, is more sensitive than traditional screens searching for strict growth inhibitors, can be tuned to provide high target specificity, and can be structured so that more biological information on test compounds is available early for evaluation and relative prioritization of hits.
  • conditionally lethal ts mutants having temperature sensitive essential gene functions are partially defective at a semi-permissive temperature. As the growth temperature is raised, the mutated gene causes a progressively crippled cellular function. It is the inherent phenotypic properties of such ts mutants that are exploited for inhibitor screening.
  • Each temperature sensitive mutant has secondary phenotypes arising from the genetic and physiological effects of the defective cellular component .
  • the genetic defect causes a partially functional protein that is more readily inhibited by drugs than the wild type protein.
  • This specific hypersensitivity can be exploited for screening purposes by establishing "genetic potentiation" screens. In such screens, compounds are sought that cause growth inhibition of a mutant strain, but not of wild type, or greater inhibition of the growth of a mutant strain than of a wild type strain. Such compounds are often (or always) inhibitors of the wild type strain at higher concentrations.
  • the primary genetic defect can cause far-reaching physiological changes in the mutant cells, even in semi-permissive conditions. Necessity for full function of biochemically related proteins upstream and downstream of the primary target may arise. Such effects cause hypersensitivity to agents that inhibit these related proteins, in addition to agents that inhibit the genetically defective cellular component. The effects of the physiological imbalance will occur through metabolic interrelationships that can be referred to as the "metabolic web". Thus, in some cases, the initial genetic potentiation screen has the ability to identify inhibitors of either the primary target, or biochemically related essential gene targets.
  • ts mutants The simplest method for validating the use of ts mutants is to select those which show a reduced growth rate at the semi-restrictive growth temperature. A reduced growth rate indicates that the essential gene function is partially defective. More specific methods of characterizing the partial defect of a mutant strain are available by biochemical or physiological assays. 2. Multi-Channel Screening Approach
  • growth conditional mutants such as ts mutants, can be used in sets to provide compoud specific susceptibility profiles. As a screening tool, the mutant inhibition profile characterizes the effects of test compounds on specific bacterial pathways . Because the mutants are more sensitive than wild type strains, compounds with weak inhibition activity can be identified.
  • Such multi-channel screening can be performed as described in Boggs et al . , SCREENING FOR MODULATORS OF BIOMOLECULES, United States Application No. 08/589,257, filed Jan 23, 1996, and International Publication No. WO96/23075, PCT/US96/00916 , which are incorporated herein by reference including drawings.
  • Growth conditional mutant strains having mutated forms of the genes described herein can beneficially be incorporated in a multi-channel screening panel .
  • Certain testing parameters for the genetic potentiation screening methods can significantly affect the identification of growth inhibitors, and thus can be manipulated to optimize screening efficiency and/or reliabilty. Notable among these factors are variable thermosensitivity of different ts mutants, increasing hypersensititivy with increasing temperature, and "apparent" increase in hypersensitivity with increasing compound concentration. a. Variable Thermosensitivity
  • S. aureus ts mutants in genetic potentiation screening, the growth of these mutants at different temperatures should be measured to determine screening temperatures for each of these mutants .
  • Different ts mutants have quite different maximum growth temperatures (MGT) .
  • MGT maximum growth temperatures
  • different mutants that have mutations in the same gene may have quite different MGTs .
  • different screening temperatures should be chosen for these mutants in order to accommodate the different growth preferences.
  • Raising screening temperature makes ts mutants more sensitive to certain compounds The ts mutants are more sensitive to potential inhibitors at elevated temperature. This temperature effect can be used to control hit rates in the screening. Higher screening temperature can be used to produce more hits for mutants that have low hit rates. Similarly, if a mutant shows a very high hit rate, the number of hits can be reduced by using lower screening temperatures to facilitate hit prioritization.
  • c Increasing compound concentrations affect apparent hypersensitivity
  • the concentration of compounds used in the screening is an important parameter in determining the hit rates and the amount of follow-up studies.
  • the concentration of 10 ⁇ g/ml has been used in piloting screening studies. Screening at concentrations ⁇ 2 ⁇ g/ml may miss at least half of the hits that would be identified at 10 ⁇ g/ml. On the other hand, screening at concentrations higher than lO ⁇ g/ml may result in a large number of low quality hits and create too much work in hit confirmation and follow-up studies.
  • a hit may appear as a growth inhibitor for both the mutant and wild type strains. This should not be a major problem since lower concentrations of the compound can be tested in the follow-up studies to differentiate its effect on the mutant and the wild type.
  • the methods of this invention are suitable and useful for screening a variety of sources for possible activity as inhibitors.
  • compound libraries can be screened, such as natural product libraries, combinatorial libraries, or other small molecule libraries.
  • compounds from commercial sources can be tested, this testing is particularly appropriate for commercially available analogs of identified inhibitors of particular bacterial genes.
  • Compounds with identified structures from commercial sources can be efficiently screened for activity against a particular target by first restricting the compounds to be screened to those with preferred structural characteristics. As an example, compounds with structural characteristics causing high gross toxicity can be excluded. Similarly, once a number of inhibitors of a specific target have been found, a sub-library may be generated consisting of compounds which have structural features in common with the identified inhibitors.
  • the ISIS computer program (MDL Information Systems, Inc.) is suitable to perform a 2D-substructure search of the Available Chemicals Directory database (MDL Information Systems, Inc.). This database contains structural and ordering information on approximately 175,000 commercially available chemical compounds. Other publicly accessible chemical databases may similarly be used.
  • Gross acute toxicity of an identified inhibitor of a specific gene target may be assessed in a mouse model.
  • the inhibitor is administered at a range of doses, including high doses, (typically 0 - 100 mg/kg, but preferably to at least 100 times the expected therapeutic dose) subcutaneously or orally, as appropriate, to healthy mice.
  • the mice are observed for 3-10 days.
  • a combination of such an inhibitor with any additional therapeutic components is tested for possible acute toxicity.
  • the particular compound that is an antibacterial agent can be administered to a patient either by itself, or in combination with another antibacterial agent, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient (s) .
  • a combination of an inhibitor of a particular gene with another antibacterial agent can be of at least two different types. In one, a quantity of an inhibitor is combined with a quantity of the other antibacterial agent in a mixture, e . g. , in a solution or powder mixture. In such mixtures, the relative quantities of the inhibitor and the other antibacterial agent may be varied as appropriate for the specific combination and expected treatment. In a second type of combination an inhibitor and another antibacterial agent can be covalently linked in such manner that the linked molecule can be cleaved within the cell.
  • an inhibitor and/or another antibacterial agent may be administered in pro-drug forms, i.e. the compound is administered in a form which is modified within the cell to produce the functional form.
  • a therapeutically effective amount of an agent or agents such as these is administered.
  • a therapeutically effective dose refers to that amount of the compound (s) that results in amelioration of symptoms or a prolongation of survival in a patient, and may include elimination of a microbial infection.
  • Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e . g. , for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population) .
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50 /ED 50 .
  • Compounds which exhibit large therapeutic indices are preferred.
  • the data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. It is preferable that the therapeutic serum concentration of an EspA/EspB inhibitor should be in the range of 0.1-100 ⁇ g/ml.
  • the therapeutically effective dose can be estimated initially from cell culture assays.
  • a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 as determined in cell culture Such information can be used to more accurately determine useful doses in humans.
  • Levels in plasma may be measured, for example, by HPLC.
  • the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See, e . g. , Fingl et al., in THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 1975, Ch. 1 p. 1) . It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity) . The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient.
  • Suitable routes may include oral, rectal, transdermal, vaginal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, just to name a few.
  • the agents of the invention may be formulated in aqueous solutions, preferably in physio- logically compatible buffers such as Hanks ' s solution, Ringer's solution, or physiological saline buffer.
  • physio- logically compatible buffers such as Hanks ' s solution, Ringer's solution, or physiological saline buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • compositions of the present invention in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection.
  • the compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art, into dosages suitable for oral administration.
  • Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
  • these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers including excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • the preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.
  • compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levitating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • compositions for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose,, hydroxypropyl- methyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP) .
  • disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasti- cizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added .
  • DNA sequences derived from the identified genes are also useful as probes to identify the presence of bacteria having the particular gene or, under suitable conditions, a homologous gene.
  • probes are useful as reagents to identify DNA chains which contain a sequence corresponding to the probe, such as for identifying clones having a recombinant DNA insert (such as in a plasmid) .
  • a probe is used which will uniquely hybridize with that sequence.
  • probe sequences from variable regions can be selected, for example, by selecting probe sequences from variable regions, using hybridization conditions of suitably high stringency, and using a sufficiently long probe (but still short enough for convenient preparation and manipulation.
  • probes are greater than 10 nucleotides in length, and more preferably greater than 15 nucleotides in length. In some cases, it is preferable that a probe be greater than 25 nucleotides in length.
  • probes based on the specific genes and sequences identified herein can be used to identify the presence of homologous sequences (from homologous genes) . For such purposes it is preferable to select probe sequences from portions of the gene which are not highly variable between homologous genes .
  • the stringency of the hybridization conditions can be reduced to allow a low level of base mismatch.
  • primers are also useful as primers for PCR.
  • Such primers are useful as reagents to amplify the number of copies of one of the identified genes or of a homologous gene.
  • probes it is preferable that the primers specifically hybridize with the corresponding sequence associated with one of the genes corresponding to SEQ ID NO. 1-3. Those skilled in the art understand how to select and utilize such primers .
  • Example 1 HEPA Screening with espAB ts mutant
  • the essential sensor pair espAB is used as the target of the HEPA screen (hypersensitivity in the espAB pathway) , which is designated to detect inhibitors of EspA and/or EspB function.
  • the expected cellular location and general function of EspA and B is shown in Fig. 5, indicating that the EspB product is believed to locate to the cell membrane.
  • the HEPA screen is a genetic potentiation screen and is summarized in the following.
  • NT372 cells and isogenic wild type parent cells are grown overnight on TSA plates at 30°C to isolate single colonies.
  • a single colony of each cell type is recovered from the plates and inoculated into 3 ml of Mueller-Hinton (MH) broth. While these cells are incubating, screening plates are prepared by adding 40 ⁇ l of MH broth into each well of 96-well microtiter plates; test compounds are then added to the screening plates to achieve a 4 ⁇ g/ml screening concentration for synthetic compounds or a 1:1000 dilution of a stock extract for natural products screening. When the OD600 of the cell cultures reaches 0.2-0.3, the cells are diluted 1:1000 with MH broth and 50 ⁇ l added to wells in the screening plates.
  • Blank wells and untreated controls for NT372 and WT are included in all screening plates.
  • the inoculated screening plates are moved to a 37°C incubator and allowed to incubate for 20 hours. This incubation temperature represents a maximum growth temperature for the NT372 mutant. Cells growing at this temperature have reduced amounts of functional EspAB and so are sensitive to compounds that specifically target the EspA and EspB proteins .
  • Hit-compounds were defined by the relative percentage of growth inhibition of NT372 and isogenic wild type cells when both cell types are exposed to a given test compound. Percent inhibition for each strain is calculated as: [1- (OD600 cpd well - OD600 blank well)/(OD600 no cpd well - OD600 blank well] X 100.
  • hits are defined as those compounds that inhibit the growth of NT372 ⁇ 70% and WT cells ⁇ 90%.
  • hits are defined as class AA (%Inh NT372 ⁇ 70% and %Inh NT372 - %Inh wt ⁇ 90) or class A (%Inh NT372 ⁇ 70% and %Inh NT372 - %Inh wt ⁇ 70) .
  • HEPA screen hit progression - (genetic and biochemical filters)
  • This assay provides a comparative analysis of the activity of a hit in a titration series (128 ⁇ g/ml to 0.03 ⁇ g/ml) against WT, NT372, and the complemented NT372 mutant, SAM533.
  • Strain SAM533 reverses the NT372 mutant phenotype, because it contains a plasmid encoding wild type espAB; thus, compounds that specifically target EspAB are not active against SAM533 as hypersensitivity to the hit-compound is eliminated by restoring normal levels of EspAB to the cell .
  • Synthetic compounds that have a WT and SAM533 MIC ⁇ 32 ⁇ g/ml and a NT372 MIC ⁇ 8 ⁇ g/ml are retained for further analysis.
  • natural product hits are examined in a titration series (2% to 0.0009%) using the same strains; extracts that show a four-fold difference in sensitivity to WT/SAM533 and
  • NT372 are retained for further examination.
  • An example of the titration series validation of a HEPA screen natural products hit is shown in Figure 6.
  • Hit evaluation can be extended through the use of biochemical assays to determine if hit compounds specifically affect the functioning of purified EspA and EspB components.
  • the companion in vi tro biochemical screen is set up using purified EspA and EspB proteins, which can be achieved expressing the espAB gene sequences . Leads identified from the specificity-titration assay will be examined for acceptable chemical structure, then utilized for analysis in the EspAB biochemical assay.
  • This strategy for Stage I combines the powerful screening ability of a genetic-based search for EspAB inhibitors with a direct demonstration of EspAB targeting using the purified proteins.
  • the synthetics pilot comprised 11,200 compounds with a hit rate of 0.43% (8 hits total) .
  • the natural products pilot examined 4,800 extracts and identified 31 class AA and class A hits (0.65% hit rate) .
  • AAAGATAAAC GTAGACAATA AAATCTTTAT TAGACGTACA AACATATGCT ACTGTCAACA 240
  • AAAAATGATA AAATAATATT AATGATTTAA GAAAAGAGGT TTATGCAAAT GGCTAGAAAA 660
  • CTACAATCCC TTCATACTAA ACTTGTAATT GTTTATGTAT TACTGATTAT CATTGGTATG 1440
  • ATTCGTATTA AAGATAATGG CATTGGTATT CCTATCAATA AAGTCGATAA GATATTCGAC 3000
  • GAAAGTACCA AATCATTTCA ATTTCAATCG TTTGGTCATA GATCTTGATG CTGATGATAA 3660
  • GCTTTAGCAT TTAATAACTT GTCTAAACGT GTACAAGAAG CGCAGGCTAA TACTGAAAGT 780 GAGAAACGTA GACTGGACTC AGTTATCACC CATATGAGTG ATGGTATTAT TGCAACAGAC 840

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des séquences de désoxyribonucléotide (ADN) isolé ou purifié, utiles pour la mise au point d'agents antibactériens, qui contiennent les séquences de codage des gènes bactériens qui codent pour les constituants d'une paire régulatrice binaire. L'invention concerne également des séquences d'ADN isolé ou purifié qui sont des portions de ces gènes bactériens, lesquels sont utiles comme sondes pour identifier la présence du gène correspondant ou la présence d'une bactérie contenant ce gène. Sont également décrites des cellules mutantes hypersensibles contenant un gène mutant correspondant à l'une quelconque des séquences identifiées, ainsi que des méthodes de détection d'agents antibactériens à l'aide de ces cellules hypersensibles. L'invention concerne d'autre part des méthodes pour traiter des infections bactériennes en administrant un agent antibactérien actif contre l'une des cibles identifiées, ainsi que des compositions pharmaceutiques efficaces dans de tels traitements.
PCT/US1997/023912 1995-09-15 1997-12-23 Genes essentiels de staphylococcus aureus histidine proteine kinase WO1999032657A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU59033/98A AU5903398A (en) 1997-12-23 1997-12-23 Staphylococcus aureus histidine protein kinase essential genes
PCT/US1997/023912 WO1999032657A1 (fr) 1997-12-23 1997-12-23 Genes essentiels de staphylococcus aureus histidine proteine kinase
US09/082,077 US6514746B1 (en) 1995-09-15 1998-05-20 Staphylococcus aureus histidine protein kinase essential genes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/023912 WO1999032657A1 (fr) 1997-12-23 1997-12-23 Genes essentiels de staphylococcus aureus histidine proteine kinase

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US71371896A Continuation-In-Part 1995-09-15 1996-09-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/082,077 Continuation-In-Part US6514746B1 (en) 1995-09-15 1998-05-20 Staphylococcus aureus histidine protein kinase essential genes

Publications (1)

Publication Number Publication Date
WO1999032657A1 true WO1999032657A1 (fr) 1999-07-01

Family

ID=22262372

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/023912 WO1999032657A1 (fr) 1995-09-15 1997-12-23 Genes essentiels de staphylococcus aureus histidine proteine kinase

Country Status (2)

Country Link
AU (1) AU5903398A (fr)
WO (1) WO1999032657A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000068360A1 (fr) * 1999-05-12 2000-11-16 Smithkline Beecham Corporation Histidine kinase, 636 hk, de staphylococcus aureus
US6346391B1 (en) 1999-07-22 2002-02-12 Trustees Of Tufts College Methods of reducing microbial resistance to drugs
WO2003029484A3 (fr) * 2001-09-28 2003-07-31 Upjohn Co Procedes et materiaux antimicrobiens
WO2001077365A3 (fr) * 2000-04-06 2003-08-21 Upjohn Co Procedes et materiaux antimicrobiens
WO2017032909A1 (fr) 2015-08-26 2017-03-02 Universidad Pública de Navarra Souches mutantes de staphylococcus aureus avec systèmes tcs inactivés multiples
CN112592906A (zh) * 2021-01-04 2021-04-02 浙江大学 一种由深海噬菌体编码的组氨酸蛋白激酶

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023075A1 (fr) * 1995-01-23 1996-08-01 Microcide Pharmaceuticals, Inc. Procedes de triage pour les modulateurs de biomolecules
WO1997011690A2 (fr) * 1995-09-29 1997-04-03 Microcide Pharmaceuticals, Inc. Inhibiteurs des voies de regulation
EP0786519A2 (fr) * 1996-01-05 1997-07-30 Human Genome Sciences, Inc. Polynucléotides et séquences de Staphylococcus aureus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023075A1 (fr) * 1995-01-23 1996-08-01 Microcide Pharmaceuticals, Inc. Procedes de triage pour les modulateurs de biomolecules
WO1997011690A2 (fr) * 1995-09-29 1997-04-03 Microcide Pharmaceuticals, Inc. Inhibiteurs des voies de regulation
EP0786519A2 (fr) * 1996-01-05 1997-07-30 Human Genome Sciences, Inc. Polynucléotides et séquences de Staphylococcus aureus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKASHI KAMOGASHIRA ET AL: "A SCREENING METHOD FOR CELL WALL INHIBITORS USING A D-CYCLOSERINE HYPERSENSITIVE MUTANT", JOURNAL OF ANTIBIOTICS, vol. 41, no. 6, 1 June 1988 (1988-06-01), pages 803 - 806, XP000570328 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000068360A1 (fr) * 1999-05-12 2000-11-16 Smithkline Beecham Corporation Histidine kinase, 636 hk, de staphylococcus aureus
US6194174B1 (en) 1999-05-12 2001-02-27 Smithkline Beecham Corporation Histidine kinase, 636 HK, of staphylococcus aureus
US6346391B1 (en) 1999-07-22 2002-02-12 Trustees Of Tufts College Methods of reducing microbial resistance to drugs
US6677133B2 (en) 1999-07-22 2004-01-13 Trustees Of Tufts College Methods of reducing microbial resistance to drugs
US7026136B2 (en) 1999-07-22 2006-04-11 Trustees Of Tufts College Methods of reducing microbial resistance to drugs
WO2001077365A3 (fr) * 2000-04-06 2003-08-21 Upjohn Co Procedes et materiaux antimicrobiens
US6764823B2 (en) 2000-04-06 2004-07-20 Pharmacia & Upjohn Company Antimicrobial methods and materials
WO2003029484A3 (fr) * 2001-09-28 2003-07-31 Upjohn Co Procedes et materiaux antimicrobiens
WO2017032909A1 (fr) 2015-08-26 2017-03-02 Universidad Pública de Navarra Souches mutantes de staphylococcus aureus avec systèmes tcs inactivés multiples
CN112592906A (zh) * 2021-01-04 2021-04-02 浙江大学 一种由深海噬菌体编码的组氨酸蛋白激酶

Also Published As

Publication number Publication date
AU5903398A (en) 1999-07-12

Similar Documents

Publication Publication Date Title
Blum et al. Excision of large DNA regions termed pathogenicity islands from tRNA-specific loci in the chromosome of an Escherichia coli wild-type pathogen
Guenzi et al. A two‐component signal‐transducing system is involved in competence and penicillin susceptibility in laboratory mutants of Streptococcus pneumoniae
Zheng et al. Absence of the KhpA and KhpB (JAG/EloR) RNA‐binding proteins suppresses the requirement for PBP2b by overproduction of FtsA in Streptococcus pneumoniae D39
Lau et al. A functional genomic analysis of type 3 Streptococcus pneumoniae virulence
Belland et al. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone‐resistant isolates
Koronakis et al. The secreted hemolysins of Proteus mirabilis, Proteus vulgaris, and Morganella morganii are genetically related to each other and to the alpha-hemolysin of Escherichia coli
Jones et al. Identification of Streptococcus agalactiae virulence genes in the neonatal rat sepsis model using signature‐tagged mutagenesis
Klee et al. Molecular and biological analysis of eight genetic islands that distinguish Neisseria meningitidis from the closely related pathogen Neisseria gonorrhoeae
US8071111B2 (en) Virulence of Streptococci
US20200109395A1 (en) Genetic systems that defend against foreign dna and uses thereof
JP2008154584A (ja) 抗菌方法と材料
Bliss et al. Polysialic acid export in Escherichia coli K1: the role of KpsT, the ATP-binding component of an ABC transporter, in chain translocation
Robertson et al. Vancomycin tolerance induced by erythromycin but not by loss of vncRS, vex3, or pep27 function in Streptococcus pneumoniae
Huang et al. The cytoplasmic loops of AgrC contribute to the quorum-sensing activity of Staphylococcus aureus
WO1999032657A1 (fr) Genes essentiels de staphylococcus aureus histidine proteine kinase
US20090298713A1 (en) Polynucleotides which are of nature b2/d+ a- and which are isolated from e. coli, and biological uses of these polynucleotides and of their polypeptides
JP2004512817A (ja) 大腸菌から単離される、ｂ２／ｄ＋ａ−型のポリヌクレオチド、ならびにこれらのポリヌクレオチドとそのポリペプチドの生物学的使用
US20100261618A1 (en) Identification of genes implicated in the virulence of streptococcus agalactiae
US20040096973A1 (en) Environmentally regulated genes of Streptococcus suis
US6514746B1 (en) Staphylococcus aureus histidine protein kinase essential genes
Périchon et al. Glycopeptide resistance
US6764823B2 (en) Antimicrobial methods and materials
Halling et al. Intrinsic and selected resistance to antibiotics binding the ribosome: analyses of Brucella 23S rrn, L4, L22, EF-Tu1, EF-Tu2, efflux and phylogenetic implications
US7258984B2 (en) Compositions and methods for identifying agents which regulate autolytic processes in bacteria
US20030021813A1 (en) Essential bacteria genes and genome scanning in Haemophilus influenzae for the identification of 'essential genes'

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载